Authors

Latest:

Dr. Bota on Marizomib in Patients with Glioma

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

Daniela Bota, MD, UC Irvine Medical Center

Daniela Molena, MD

Latest:

Dr. Molena on Lung-Sparing Surgery in Early-Stage Lung Cancer

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.

Danielle Brander, MD

Latest:

Dr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLL

Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Danielle Bucco

Latest:

Standard of Care Continues to Shift in RCC

Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.

Danielle M. Brander, MD

Latest:

Dr. Brander on Targeted Agents in CLL

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses targeted agents in chronic lymphocytic leukemia (CLL).

Danielle Ternyila

Latest:

Camrelizumab/Apatinib Shows Promising Activity in Second-Line Esophageal Squamous Cell Carcinoma

January 15, 2021 - A novel combination comprised of camrelizumab and apatinib was found to have promising clinical efficacy with an acceptable safety profile when used as a second-line treatment in patients with esophageal squamous cell carcinoma.

Danielle Townsley, MD

Latest:

Dr. Townsley on Screening for GATA2 in At-Risk Patients for MDS, AA, and AML

Danielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses a study which examined screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).

Danny Rischin, MD

Latest:

Dr. Rischin on KEYNOTE-048 Results in Head and Neck Squamous Cell Carcinoma

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.

Danny Rischin, MD, MBBS, FRACP

Latest:

Dr. Rischin on the FDA Approval of Cemiplimab for CSCC

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the FDA approval of cemiplimab for the treatment of patients with cutaneous squamous cell carcinoma.

Daphne Dumoulin, MD

Latest:

Dr. Dumoulin on NVALT 12 Data in NSCLC

Daphne Dumoulin, MD, discusses the NVALT 12 study, a trial examining paclitaxel/carboplatin/bevacizumab inducing peripheral effector CD8 T-cell proliferation that could be prone to treatment in checkpoint inhibitors in patients with non–small cell lung cancer.

Dara L. Aisner, MD, PhD

Latest:

Dr. Aisner on the Limitations of Molecular Profiling

Dara L. Aisner, MD, PhD, associate professor in the department of Pathology at the University of Colorado School of Medicine, discusses the limitations of molecular profiling.

Darcie Hurteau, MBA

Latest:

Growing Pains: OCM Results Need Close Look

Darcie Hurteau, MBA, and Alyssa Dahl, PhD, MPH, discuss the growing pains of the Oncology Care Model, a complicated payment program that is still establishing administrative processes.

Darcy Burbage, RN, MSN, AOCN, CBCN

Latest:

Darcy Burbage Discusses the Role of Nurses in Treating CIPN

Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses the role nurses play in treating patients with chemotherapy-induced peripheral neuropathy (CIPN).

Darcy Lewis

Latest:

Breast Cancer Expert Focuses on Decoding Biomarkers

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

Daria V. Babushok, MD, PhD

Latest:

Dr. Babushok on Treatment Advances in Paroxysmal Nocturnal Hemoglobinuria

Daria V. Babushok, MD, PhD, discusses treatment advances in paroxysmal nocturnal hemoglobinuria.

Dario C. Altieri, MD

Latest:

Institute Develops Fresh Bench-to-Bedside Model Through Community Ties

In more than 40 years as a National Cancer Institute (NCI)-designated cancer center-and the first center in the network devoted purely to basic research-The Wistar Institute has built a reputation for furthering the sort of scientific research that will improve clinical cancer medicine.

Darren S. Sigal, MD, Scripps Green Hospital

Darrin M. Beaupre, MD

Latest:

Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell Lymphoma

Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).

Davendra P. S. Sohal, MD, MPH

Latest:

Cleveland Clinic Study Finds Barriers to Precision Oncology in a Real-World Test

Although precision oncology has promise, its success hinges on the availability of clinical trials of targeted therapies.